Related Experiment Video
Updated: Aug 11, 2026

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
Published on: February 7, 2021
Ready-to-use, spheronized drug particles-embedded iron(III)-reinforced carboxymethyl cellulose hydrogels as novel
Min Young Jeong1, Do Myeong Shin1, In Gyu Yang1
1College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan, Chungnam 31116, South Korea.
Abstract:
This study aimed to construct a ready-to-use, spheronized drug particle-embedded iron(III)-reinforced carboxymethyl cellulose hydrogel (Fe3+-CMC HG) as a novel long-acting injectable (LAI) platform for hydrophobic drugs. Dutasteride (DTS), a lipophilic 5α-reductase inhibitor prescribed for benign prostatic hyperplasia, was selected as a model compound. Uniform spherical DTS particles (∼180 μm) were fabricated using a dual centrifugation technique, with excellent flowability. Low-molecular-weight CMC (90 kDa, 100 mg/mL) formed a mechanically reinforced HG with 0.1% (w/v) Fe3⁺ (designated 90K-0.1) through coordination with carboxyl and hydroxyl groups, yielding high viscoelasticity and restricted spreading. Prior to administration, the spherical drug particles were homogeneously incorporated into the CMC HG via hydrogen bonding through two-syringe mixing process, preserving their original particle size and crystallinity. In vivo studies in rats exhibited that intramuscular administration of 90K-0.1 provided a markedly prolonged pharmacokinetic profile over 56 days, comparable to that of native high-molecular-weight CMC HG (700 kDa, 20 mg/mL) and a poly(lactic-co-glycolic acid)-based in situ forming implant (ISFI). Furthermore, Fe3⁺-CMC HG elicited substantially reduced local inflammation at the injection site compared with native CMC HG and ISFI. Collectively, these findings support Fe3⁺-CMC HG as an effective and biocompatible LAI platform for hydrophobic drugs such as DTS.
Related Concept Videos
Modified-Release Drug Delivery Systems: Stimuli-Activated
Ophthalmic Drug Delivery Systems
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Oral Drug Delivery Systems: Delayed-Release Systems
Modified-Release Drug Delivery Systems: Rate-Programmed II
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

